Happy Holidays from Masimo!

This has been an exciting and successful year for all of us here at Masimo, and we wish to share our success with charitable organizations that you choose by making a donation to them on your behalf.

This year, we have seen increasingly strong clinical adoption of our revolutionary Masimo SET Read-Through Motion and Low Perfusion pulse oximetry technology, with nearly 400,000 systems in use worldwide. We are especially grateful that we were able to introduce the Second Revolution in Oximetry-Masimo Rainbow SET Pulse CO-Oximetry-and that it has already been responsible for saving lives by allowing clinicians to diagnose, treat and manage their patients' condition through the continuous and noninvasive measurement of carboxyhemoglobin, methemoglobin, oxygen saturation, perfusion index and pulse rate. Building on this solid foundation, we plan to introduce a number of new technologies in 2007 that continue our mission to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and new applications. As a show of gratitude to those of you who have supported the cause for better care-and to fulfill our heart-felt responsibility to give something back to some of the organizations committed to better care and a better world-Masimo would like to donate $10 to the charity of your choice. We will make this donation in the name of each person who is an official member of Livewire as of today and who responds to this Livewire with their choices from the list below: Amnesty International Opportunity International CARE Swan Foundation in Medical Ethics Doctors Without Borders UNICEF Huntington's DSA United Way Make-a-Wish Foundation World Vision March of Dimes 911 Research

Please send us an e-mail at: charity@masimo.com to specify your selection. Only requests by e-mail to this address will be processed.

We also would appreciate any comments or suggestions you might have that would help us as we strive to fulfill our mission and adhere to our guiding principles.

Masimo Mission Statement:

Improving patient outcomes and reducing cost of care by taking noninvasive monitoring to new sites and applications.

Masimo Guiding Principles:

• Remain faithful to your promises and responsibilities.
• Thrive on fascination and accomplishment and not on greed and power.
• Make each day as fun as possible.
• Strive to make each year better than the year before, both personally and for the Team.
• Do what is best for patient care.

Thank You!

New Clinical Research: Masimo Rainbow SET Pulse CO-Oximetry Technology Shown Effective and Efficient in Detecting Carbon Monoxide Poisoning in Multiple Clinical Settings

New studies presented at the 2006 AARC Congress reinforce growing clinical evidence
on the efficacy of Masimo's breakthrough Rainbow SET Technology

Irvine, California December 19, 2006 - Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, reported that two new independent studies and one case report were presented last week at the 2006 American Association of Respiratory Care (AARC) Congress in Las Vegas, each highlighting the significant clinical benefits to be gained by noninvasively screening patients for carbon monoxide poisoning using the "rapid," "inexpensive" and "reliable" Masimo Rainbow SET Pulse CO-Oximetry technology.

In a study led by Dr. Robert Partridge and Dr. Gregory Jay of Rhode Island Hospital at Brown University Medical School, a team of researchers performed a study to assess baseline carbon monoxide (CO) levels of nearly 5,000 patients presenting to the emergency room. To accomplish this, all pulse oximeters in the emergency department (ED) were replaced with Masimo Rainbow SET Pulse CO-Oximeters and the ED staff began assessing baseline carboxyhemoglobin (COHb) levels of all adult patients as part of the standard triage process. In addition to confirming suspected cases of CO toxicity (COT) from smoke inhalation, there were nine unsuspected cases of COT discovered, in just three months, in patients who presented with non-specific symptoms or unrelated complaints. Toxic COHb levels ranged from 16-33% and were confirmed with an invasive laboratory blood test. If this rate were indicative of all US hospitals, it would equate to as many as 50,000 cases of unsuspected CO toxicity annually.

The study concluded that the use of Masimo Rainbow SET as a noninvasive test for COT can effectively and efficiently be performed at ED triage, and that "unsuspected COT may be identified using noninvasive COHb screening and the prevalence of COT may be higher than previously recognized."

The team from Brown University also presented a case report of a previously healthy 52-year old non-smoking female who was brought to the ED complaining of nausea, headache, dizziness, and feeling cold. The patient had no history of carbon monoxide exposure. The Masimo Rainbow SET device recorded an SpCO level of 33%, which was later confirmed with an invasive laboratory measurement. After interviewing the woman, clinicians learned that her utilities had been shut off and she was running a gas-powered generator in her basement.

In the report, researchers said that since early CO toxicity shares symptoms with other more common illnesses, "physicians must maintain a high index of suspicion to avoid incorrect diagnosis, management and disposition. Unrecognized CO poisoned patients returned to the site of exposure may develop more serious CO toxicity." They added that the noninvasive testing provided by Masimo Rainbow SET technology "is a rapid, inexpensive method for screening large numbers of patients for CO toxicity and identifying unsuspected cases that might otherwise be missed."

Finally, a group of researchers at the Erlanger Health System in Chattanooga, TN used the Masimo Rainbow SET technology to assess CO levels on 136 patients who presented to the outpatient pulmonary lab for arterial blood gas (ABG) draws to evaluate patient's smoking history as well as 21 patients who presented with burns and inhalation injuries in the ED who also received ABGs. As a result of these tests, the researchers concluded that the Masimo Rainbow SET Pulse CO-Oximeter "performed well in both the pulmonary and the Emergency Department environments, with an extremely small bias compared to CO-oximetry measured COHb." They added that based on their study, the technology was "quite reliable at detecting elevated CO levels in patients presenting to the pulmonary lab or emergency department."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations-establishing the technology as the "gold standard" pulse oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Contact:
Tom McCall
Masimo Corporation
949-297-7075

Evaluation of a New Pulse CO-Oximeter: Noninvasive Measurement of Carboxyhemoglobin in the Outpatient Pulmonary Lab and Emergency Departments. Layne T, Snyder C, Brooks D, Enjeti. Pulmonary Physiology Department, Erlanger Health System, Chattanooga, TN.

Non-Invasive Carboxyhemoglobin Monitoring: Screening Emergency Department Patients for Carbon Monoxide Exposure. Partridge R, Chee KJ, Suner S, Sucov A, Jay G. Department of Emergency Medicine, Rhode Island Hospital, Brown Medical School, Providence, RI.

Unsuspected Carbon Monoxide Toxicity Detected by Non-Invasive Monitoring: A Case Report. Partridge R, Chee KJ, Suner S, Sucov A, Jay GD. Department of Emergency Medicine, Rhode Island Hospital, Brown Medical School, Providence, RI

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet and Pulse CO-Oximeter are trademarks of Masimo Corp.

Breaking Study: Masimo Blue Sensor Proven Most Accurate in Measuring Oxygen Saturation on Babies with Cyanotic Heart Disease

New study presented at the 2006 Respiratory Care Congress concludes that Masimo Blue sensor is only sensor to demonstrate acceptable accuracy on this low saturation patient population

Irvine, California December 13, 2006 - Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, reported that a new independent study presented today at the 2006 American Association for Respiratory Care (AARC) Congress in Las Vegas, concluded that the Masimo Blue sensor is the most accurate technology for monitoring babies with cyanotic congenital heart disease. This patient population has represented a difficult challenge for pulse oximeters due to the patients' unique physiology and the need to keep their saturation at a low level. The researchers compared Masimo SET Radical using the Masimo Blue sensor with the Nellcor N600 LoSat technology using a Max-I sensor and concluded that only the Masimo Blue sensor demonstrated acceptable accuracy on this patient population.

The study entitled, "New Pulse Oximetry Sensors with Low Saturation Accuracy Claims - A Clinical Evaluation" was conducted at The Toronto Hospital for Sick Children by a research team headed by Dr. Peter Cox. The researchers indicated that, despite many advances in pulse oximetry technology, accuracy on patients with low saturations was still a problem. Dr. Cox's specific interest was the performance of pulse oximeters on babies with cyanotic congenital cardiac lesions (CCCL) which typically are kept at very low blood oxygen levels to maintain a balance of blood flow to the lungs and the body. He explained that careful maintenance of oxygen saturation levels on these babies is critical to their survival. The study was prompted by the fact that two pulse oximetry manufacturers have recently introduced products specifically suited for this patient population. Masimo introduced the Blue sensor in 2005 and Nellcor introduced their LoSat technology in 2006.

Dr. Cox and his team compared the Masimo Blue sensor to a Nellcor N600 with LoSat technology on babies with CCCL. The researchers found a statistically significant difference between the Masimo and Nellcor pulse oximeters and concluded, "Despite advances in technology, only the new Masimo Blue sensor demonstrates acceptable accuracy as demonstrated by a smaller bias, precision and A_rms."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations-establishing the technology as the "gold standard" pulse oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Contact:
Tom McCall
Masimo Corporation
949-297-7075

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet and Pulse CO-Oximeter are trademarks of Masimo Corp.

New Pulse Oximetry Sensors with Low Saturation Accuracy Claims - A Clinical Evaluation. Cox PN. Hospital for Sick Children, Toronto, Canada, 2006.

Dräger Medical and Masimo Announce Expanded Relationship

Breaking Studies: Masimo SET Pulse Oximetry Technology Again Shown to be Most Effective

New studies presented at last week's 2006 ASA Annual Meeting add to the more than 100 independent studies validating Masimo SET as the gold standard; technology is the foundation that enables Pulse CO-Oximetry

Irvine, California October 27, 2006 - Masimo, the inventor of Pulse CO-Oximetry and read-through motion and low perfusion pulse oximetry, reported that multiple independent studies were presented last week at the 2006 American Society of Anesthesiology (ASA) Annual Meeting in Chicago, each reinforcing the superiority of Masimo SET in providing accurate, reliable pulse oximetry readings. In the studies, Masimo SET was shown to "work better for patient safety" during the most difficult clinical conditions of motion and low peripheral perfusion.

Masimo SET is the foundational technology that allowed the company to introduce Masimo Rainbow SET Pulse CO-Oximetry-the first and only monitoring platform that allows for the continuous and noninvasive measurement of carbon monoxide (COHb), methemoglobin (MetHb), oxygen saturation (O2Hb), pulse rate and perfusion index. Masimo introduced the first bedside monitors, Radical-7, to feature this groundbreaking technology at last week's ASA meeting, and hosted a pre-ASA symposium on clinical implications of noninvasive and continuous monitoring of MetHb and COHb using Masimo Rainbow SET. Specific findings of the studies include:

Masimo shown to be "better for patient safety"

In a study entitled "Comparison of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers" performed by Nitin Shah, MD and Laverne Estanol, MS at the VA and UC Irvine Medical Centers in Long Beach, CA, the researchers stated that pulse oximeter accuracy is often compromised by low perfusion states and motion artifact that can jeopardize patient safety in the OR, PACU, and ICU, adding that "manufacturers keep improving their technology in an attempt to solve this problem". To asses the effectiveness of the newest technologies, the study compared Masimo SET with the Nellcor N-600 and GE Datex-Ohmeda TruSat, under conditions of low perfusion and motion in hypoxic and normoxic states in volunteers between the ages of 18 and 40 years old.

The results showed that Masimo had the lowest level of false alarms, performing nearly six times better than the Nellcor N600. For the rate of missed true events, the Masimo unit again had the lowest level, performing 17 times better than the Nellcor N600. The researchers concluded that during hypoxic/normoxic and low perfusion states, "Nellcor N-600 and Datex Ohmeda TruSat performed inferior to Masimo Radical with respect to maintaining accurate readings during both machine generated and self generated motions". They added that "it appears from this study that Masimo Radical may work better for patient safety, especially at critical times in OR, PACU, and ICU."¹

In a separate report entitled "Impact of Motion and Low Perfusion on SpO2 & Pulse Rate in Three New Generation POs in Volunteers", Shah and Estanol found that the Masimo SET device was within 7 percent of the true saturation measurement 98 percent of the time as compared to 72.7 percent for the Nellcor N-600, concluding that Masimo "performed the best in this vigorous testing schedule for both SpO2 and pulse rate" and added that "Masimo will give reliable SpO2 & PR values for a greater period of time as compared to Datex-Ohmeda TruSat and Nellcor N-600 in the OR, PACU, and ICU". ²

In another abstract, entitled "Failure Rates & Recovery Times of New Generation POs during Motion and Low Perfusion in Volunteers", Shah and Estanol explained that patient movement and low perfusion due to lower temperature is common in the PACU and OR, especially during extubation. They examined the failure rate, the percentage of times that the monitor was more than 7 percent off from the actual SpO2 reading, and the recovery time, the average amount of time taken for the monitor to return to accurate values. The most significant finding was the difference in SpO2 failure rates with Masimo SET was more than 10 times better than Nellcor N-600, concluding that "Masimo may serve better for patient safety."³

Masimo accuracy cited as beneficial to children with cyanotic congenital heart disease

Additional studies presented at the ASA included "The Accuracy of Masimo SET and Nellcor N-595 in Children with Cyanotic Congenital Heart Disease" conducted by Yuichiro Toda, M.D., Mamoru Takeuchi, M.D., Tatsuo Iwasaki, M.D., Kazuyoshi Shimizu, M.D., Kiyoshi Morita, M.D. from Okayama University Medical School in Japan. In this study, the researchers compared the performance of Masimo SET and specifically Masimo's Blue sensor to the Nellcor 595 and the Max-I Sensor on infants with cyanotic congenital heart disease, a patient population with a reputation for causing erroneous pulse oximetry readings. The Masimo Blue sensor was specifically designed for this patient population. The researchers found that overall, the bias (error) of the Nellcor sensor was approximately 18 times that of Masimo's, but on the sickest patients with the lowest blood flow, the Nellcor bias (error) was more than 21 times that of the Masimo Blue Sensor prompting the researchers to conclude "Masimo blue sensor presented smaller bias compared with Nellcor sensor" and that "Nellcor presented wider bias during low perfused state than that at normal perfusion". They concluded that of the two technologies, "Masimo blue sensor provides the accurate measurement of pulse oximetry in patients with cyanotic congenital heart disease". ⁴

These and all the studies referencing the superiority of Masimo technology were presented in abstract form at the ASA Annual Meeting and are available for viewing on the ASA website at www.asa-abstracts.com.

Joe E. Kiani, Chairman & CEO of Masimo stated; "It is gratifying to see so many independent researchers taking the time to evaluate Masimo SET and to communicate the positive impacts on patient care and safety that can be realized through its use. We are confident that the introduction of Masimo Rainbow SET will further enable clinicians to do what's right for patient care by giving them a more accurate picture of their patients' status with the continuous and noninvasive monitoring of oxyhemoglobin, methemoglobin, carboxyhemoglobin, perfusion index and pulse rate."

About Masimo

Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations- establishing the technology as the "gold standard" pulse oximetry and substantially contributing to improved patient outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

1. Nitin Shah, M.D., Laverne Estanol, M.S. Anesthesiology, Long Beach VA Medical Center; UC Irvine Medical Center, Long Beach, California. Anesthesiology 2006; 105: A929
2. Nitin Shah, M.D., Laverne Estanol, M.S. Anesthesiology, Long Beach VA Medical Center; UC Irvine Medical Center, Long Beach, California. Anesthesiology 2006; 105: A1433
3. Nitin Shah, M.D., Laverne Estanol, M.S. Anesthesiology, Long Beach VA Medical Center, UC Irvine Medical Center, Long Beach, California. Anesthesiology 2006; 105: A242
4. Yuichiro Toda, M.D., Mamoru Takeuchi, M.D., Tatsuo Iwasaki, M.D., Kazuyoshi Shimizu, M.D., Kiyoshi Morita, M.D., Dept. of Anesthesiology and Intensive care medicine, Okayama University Medical School, Okayama-shi, Okayama-ken, Japan. Anesthesiology 2006; 105: A1704

Contact:
Tom McCall
Masimo Corporation
949-297-7075

Masimo, SET, Signal Extraction Technology, Rainbow, Radical, APOD, SpCO, and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Radical-7, Rad-57, SpMet and Pulse CO-Oximeter are trademarks of Masimo Corp.

Masimo Announces FDA Clearance of Radical-7, First Bedside Monitor with the Breakthrough Rainbow Technology

Masimo SET with Rainbow technology is the first and only continuous and noninvasive carboxyhemoglobin, methemoglobin, and oxyhemoglobin saturation monitor

Irvine, California October 5, 2006 --Masimo today announced it has received FDA clearance for Masimo Radical-7--the first bedside monitor to feature the award winning Rainbow technology--which will be introduced at the upcoming Annual Meeting of the American Association of Anesthesiologists October 14-18 in Chicago. Two new Radical-7 bedside monitors with different user interfaces including a color display will be available with Masimo SET with Rainbow technology, the first and only way for clinicians to continuously and noninvasively monitor their patients' carboxyhemoglobin (SpCO), methemoglobin (SpMet), oxygen saturation (SpO₂), pulse rate, and perfusion index.

Masimo SET with Rainbow Technology has already proven to be effective in detecting carbon monoxide and methemoglobin poisoning in critical situations, allowing accurate diagnosis and early treatment of life-threatening conditions.  Last month at a hospital in Southern California, a patient was diagnosed with a Rainbow monitor to have a dangerously high level of methemoglobin. Because of this timely diagnosis, the patient was immediately treated and the patient's life was saved.

Also, last month a hospital in Boca Raton, Florida used a hand-held Rainbow monitor, the Masimo Rad-57, to avert a potential disaster. Clinicians at the hospital, after using the Rad-57 to detect dangerous levels of carbon monoxide in a patient's blood, dispatched emergency services to the young man's condo complex and safely evacuated nearly 200 people from a 20-story building where a faulty generator led to carbon monoxide levels 100 times greater than normal. As a result, there were no reports of permanent injury to any of the building's residents.

"We are proud of the scientific achievement in making noninvasive and continuous measurement of SpCO and SpMet possible, but life-saving incidents like the ones noted above bring a different kind of satisfaction to those accomplishments," explained Joe Kiani, Masimo Chairman and CEO.

The Rainbow platform is based on Masimo's revolutionary and gold standard Signal Extraction Technology --the world's first and highest performance pulse oximetry technology clinically proven accurate and reliable during periods of patient motion and low peripheral perfusion. But while other pulse oximetry technologies use only two wavelengths of light to distinguish oxygenated from nonoxygenated hemoglobin, Masimo SET with Rainbow technology uses multiple (7+) wavelengths to noninvasively and continuously measure carboxyhemoglobin and methemoglobin in addition to oxygen saturation, pulse rate and perfusion index.  In addition, when used with Rainbow sensors, the Rainbow monitors employ a new probe-off technology called RAPOD, which can detect when the sensor has come off the patient more reliably than ever before.

Rainbow allows clinicians to be more confident of the accuracy of their SpO₂ readings by giving them the ability to frame those measurements with the dyshemoglobins SpCO and SpMet. Neither SpCO nor SpMet can be distinguished from, and are often reported as, SpO₂ by all other pulse oximeters, yet both are incapable of transporting oxygen, resulting in reduced blood oxygenation levels that can induce tissue hypoxemia. Peer-reviewed clinical studies have proven that the prevalence and significance of both these dyshemoglobins raise morbidity and mortality across the spectrum of acute care settings. 

The Institute for Safe Medical Practice (ISMP) states that "methemoglobinemia is unlikely to be a rare occurrence", while authors from the 2004 Johns Hopkins University School of Medicine study[i] entitled "Acquired Methemoglobinemia", concluded "drugs that cause acquired methemoglobinemia are ubiquitous in both the hospital and the outpatient setting."  The Johns Hopkins study had many key findings:

1. Acquired methemoglobinemia is ubiquitous in hospitals, from OR to the General Ward and is independent of patient's age, from 4 days of age to 86 year of age.
2. More than 20 drugs that are used frequently in hospitals cause acquired methemoglobinemia, including 'caine' anesthetics such as Benzocaine and Lidocaine, heart medications, such as nitroglycerin, inhaled nitric oxide used on premature infants and sometimes cardiac patients, and Dapsone, a powerful anti-infective which is commonly used on organ transplant, AIDS, and dermatoses patients.
3. Methemoglobinemia can cause serious injury and even death, but can be treated if detected.  During the study time, there were three near deaths and one death.
4. Nearly 20% of patients tested had elevated methemoglobin levels and 25% of the cases were found accidentally.
5. The cost of doing invasive testing of methemoglobin is $25 each time and during the 28-month period it would have cost the hospital $9 Million.

"Before the advent of Masimo SET and Rainbow Technology, it was impossible for clinicians to reliably monitor their patients continuously for methemoglobinemia and carboxyhemoglobinemia, let alone oxygen saturation, and as a result many patients suffered. We are proud to once again bridge the gap between measurement and patient condition, by breaking the technological barriers and introducing SpCO and SpMet," Kiani continued.  "But in addition to the current ability to monitor the level of SpCO and SpMet, Masimo is using the additional data delivered by the Rainbow technology platform and sensors to qualify an array of additional clinically valuable measurements.  And because Masimo SET with Rainbow technology is designed as a technology platform, hospitals can easily upgrade to these additional new noninvasive clinical measurements when they become available without acquiring new hardware."

The Radical-7 is the first pulse oximeter to have a color screen. Additionally, to provide customers with maximum flexibility in their transition to Rainbow technology, each Masimo Radical-7 is fully field upgradeable, so customers can purchase the Radical-7--which comes standard with Masimo SET SpO₂, pulse rate and perfusion index--with Rainbow parameters at the time of purchase, or have them field installed in the future.  In June, Masimo received a prestigious Medical Design Excellence Gold Award for its Rad-57 handheld  Pulse CO-Oximeter with Rainbow technology. In addition, the technology received the 2006 Application of Technology award from the Society for Technology in Anesthesia in January and was honored by the American Electronics Association as the Innovative Product winner in the Medical Technology category at its Thirteenth Annual High Tech Awards ceremony in May.

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, RAPOD, and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow, SpCO, SpMet and Pulse CO-Oximeter are trademarks of Masimo Labs.

Contact: Tom McCall
Masimo Corporation
949-297-7075

[i] Ash-Bernal R, Wise R, Wright SM. Acquired Methemoglobinemia.  A Retrospective Series of 138 Cases at 2 Teaching Hospitals. Medicine 2004; 83: 265-272.

New Masimo Rainbow SET™ Pulse CO-Oximetry™ Technology Receives Prestigious Medical Design Excellence Gold Award

Irvine, California September 5, 2006 - Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, today announced it has received a prestigious Medical Design Excellence Gold Award for its innovative new Masimo Rainbow SET Rad-57 Pulse CO-Oximeter.

The Masimo Rad-57 Pulse CO-Oximeter is the first and only device that allows clinicians to detect and continuously monitor carbon monoxide levels in the bloodstream non-invasively. In clinical studies and in the field, Masimo Rainbow SET is already proving itself effective in detecting carbon monoxide poisoning in seconds, allowing accurate diagnosis and early treatment of a life-threatening problem that is frequently misdiagnosed as flu or migraine. Masimo has also recently received FDA clearance for the noninvasive measurement of methemoglobin levels in the blood. A recent Johns Hopkins study found that methemoglobinemia, a potentially lethal condition that starves the tissues of oxygen, is much more common in hospitalized patients than previously realized. 

Joe E. Kiani, Chairman & CEO of Masimo stated, "We are honored to receive this Medical Design Excellence Gold Award.  We received a similar award years ago when we introduced the Radical Signal Extraction Pulse Oximeter, which was the first technology to measure oxygen saturation and pulse rate during motion and low perfusion.  We take much pride that the second breakthrough in oximetry is once again developed by our engineering team.   With our new Masimo Rainbow SET platform, we are collecting a much more rich data stream separated from interference, enabling us to distinguish additional blood constituents. Our clinical and engineering teams are currently working to identify and qualify additional Rainbow parameters. We thank the organizers of the MDEA program for this award and their recognition of this innovative platform, and I thank our engineering team for their brilliant efforts and tireless progress."

The Medical Design Excellence Awards competition is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so the product meets its clinical objectives. A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact: Tom McCall
Masimo Corporation
949-297-7075

American Society of Anesthesiologists Issues New Practice Guidelines for the Perioperative Management of Patients with Obstructive Sleep Apnea

Masimo announces new Patient Safety Net System that together with Masimo SET's unmatched sensitivity and specificity will help hospitals comply with the ASA guidelines

Irvine, California, August 24, 2006 - The American Society of Anesthesiologists (ASA) recently adopted practice guidelines for the perioperative management of patients with obstructive sleep apnea (OSA) to reduce the risk of adverse outcomes in patients with OSA who receive sedation, analgesia or anesthesia. OSA is a syndrome characterized by periodic, partial, or complete obstruction of the upper airway during sleep. It is well known that even patients without a history of OSA can develop OSA during perioperative phases. OSA patients are especially vulnerable during the postoperative period because protective arousal reflexes are diminished due to the effects of anesthesia and opioid analgesia. The ASA guidelines recommend preoperative screening of all surgical patients for OSA followed by a postoperative protocol of continuous pulse oximetry monitoring until the patient is no longer at risk.

Masimo, the inventor and pioneer of Read-Through Motion and Low Perfusion Pulse Oximetry, has recently introduced the RadNet Patient Safety Net System to help clinicians monitor their patients continuously and remotely. RadNet provides surveillance for up to 28 patients by either hardwired or wireless connectivity from point of care monitors to a base monitoring station. RadNet is an easy to install, easy to use system that is scaleable based on a specific hospital's needs.

The key to the success of the RadNet system is Masimo SET pulse oximetry technology, proven through more than 80 independent and objective published clinical studies to be the most reliable and accurate pulse oximeter during challenging conditions such as patient motion, low perfusion and bright lights, which can confuse other pulse oximetry technologies. Masimo's patented technology has been proven to dramatically reduce false alarms and improve detection of true alarms, especially in the challenging conditions, such as those encountered in monitoring ambulatory patients in the general care areas.

Steve Moreau, CEO of San Antonio Hospital stated, "High quality patient care and cost savings go hand in hand. When clinicians detect problems early, lives can be saved, patients will recover sooner and health care costs are lowered. Rapid Response Teams have been created to react more quickly to adverse events, but their success is dependent upon reliable and continuous monitoring of patients at risk. Technology solutions such as Masimo SET and RadNet play a critically important role in providing an early warning system for the clinicians providing care at the bedside."

Joe E. Kiani, CEO and Chairman of Masimo stated, "We applaud the ASA for recognizing the need to better care for patients post operatively and we are proud that we have created the tools to help make these recommendations realizable. Masimo SET has clearly been proven as the most reliable pulse oximeter in the world, especially in the presence of patient motion and low perfusion. We developed Signal Extraction Technology to allow patients to be monitored reliably in the general floor. In fact, since our founding in 1989, our mission has been Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications. We are delighted that our mission is consistent with the healthcare community's goals of reducing unnecessary morbidity and mortality."

Recent data suggests that the prevalence of OSA may be much greater than previously thought. A recently published study performed at Barnes Jewish Hospital in St. Louis screened 1,898 surgical patients over four months and found that over 19% of those patients had OSA.

These guidelines add to a significant existing challenge that hospitals have been coping with to better care for recovering patients after being transferred out of the intensive care units (ICU) in order to reduce the incidence of unexpected adverse patients events, often referred to as "sentinel events". This task is made difficult due to the fact that, in most cases, the ICUs are the only areas equipped to provide this level of postoperative care. Not only is there a lack of monitoring outside of the ICUs, but there are also far fewer nurses per patient. So, even if the hospital can put pulse oximeters on all of these patients, there may not be enough nurses to react to the alarms. Making this challenge even more difficult is the fact that most of the existing pulse oximeters are prone to excessive false alarms and missed true events. In a recently completed study that will be presented at the ASA's annual conference this October, the newest pulse oximeters from two of the largest manufacturers had false alarm rates of 17-28% and missed events incidence of 42-82%, while Masimo SET's false alarm rate and incidences of missed events was nearly an order of magnitude lower.

Along with RadNet, Masimo is introducing PPO+, a wireless, wearable Masimo SET pulse oximeter with optional ECG, which will allow patients that are ambulating to have their oxygen saturation, pulse rate and ECG continuously monitored via RadNet wirelessly. There are currently a variety of point of care devices that are compatible with RadNet. Masimo is planning to unveil new Masimo SET and Masimo Rainbow SET enabled monitors to further serve the growing needs of care providers, especially those in the general ward.

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 80 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corporation. RadNet, Patient Safety Net System and PPO+ are trademarks of Masimo Corporation. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact: Tom McCall
949-297-7075
tmccall@masimo.com

Masimo and Respironics Announce an Expanded Relationship, the Adoption of Masimo Rainbow SET Pulse CO-Oximetry, and Settlement of Patent Dispute

Irvine, California - August 1, 2006, Respironics, Inc. today announced that it has decided to expand its relationship with Masimo and to adopt Masimo's pulse oximetry solution for situations requiring read through motion technology across all of its business units. Until now Respironics has only used Masimo SET in certain of its sleep and respiratory products. Respironics will be gradually incorporating Rainbow SET in all Respironics products where the improved capabilities will provide clear clinical improvements. Respironics will be phasing out its Novametrix MARS oximetry product line over time but will continue to service customers until a comprehensive plan is in place. This agreement between Respironics and Masimo also constitutes a release by Masimo of Respironics and its affiliates from certain patent infringement claims and provides Respironics with access to the Masimo Rainbow SET technology.

Craig Reynolds, COO of Respironics stated, "Masimo SET is clearly the gold standard in pulse oximetry technology for its ability to reliably measure oxygen saturation and pulse rate during difficult situations, but with its new Rainbow Technology, Masimo further advances the science by being able to simultaneously measure carboxyhemoglobin and methemoglobin noninvasively, which until now could only be measured invasively. Masimo and Respironics have enjoyed a great business relationship for over 10 years. We are excited to be able to extend our existing relationship and again be one of the first companies to provide our customers with the latest advancements in noninvasive patient monitoring technology."

Joe E. Kiani, Chairman and CEO of Masimo stated, "We greatly value our relationship with Respironics and are happy to be expanding our relationship with this new agreement. Respironics was one of the first OEM users of Masimo technology, taking our revolutionary read-through motion and low perfusion pulse oximetry technology to the sleep labs and home care when that was the business they focused on. We are delighted to see Respironics not only make great headway in the hospital market with its ventilator products, but to take Rainbow SET to its customers around the world."

Respironics stated that it will not be changing its financial outlook for guidance based on the events described in this press release.

About Respironics, Inc.
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,600 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com

Contact:
Maryellen Bizzack
724-387-5006
maryellen.bizzack@respironics.com

Masimo Renews Agreement with Amerinet for Masimo SET Pulse Oximetry and Adds New Masimo Rainbow SET™ Technology

IRVINE, California - July 27, 2006 - Masimo Corporation today announced that it has renewed a three-year, dual source agreement with Amerinet, a leading health care group purchasing organization with more than 25,000 members ranging from large health systems to physician's offices to long-term care facilities. The agreement continues coverage of Masimo SET^® pulse oximetry technology and adds the company's breakthrough Masimo Rainbow SET Pulse CO-Oximetry™ in standalone monitoring devices, handhelds and sensors.

"We are pleased to announce the renewal of our agreement with Amerinet," explained Masimo Chairman and CEO Joe E. Kiani. "And we believe that Amerinet members will be pleased to continue to have access to superior Masimo SET pulse oximetry products as well as the new Masimo Rainbow SET technology that will allow for the earlier detection and treatment of an expanding number of potentially life-threatening conditions."

Masimo SET technology allows clinicians to obtain accurate pulse oximetry readings even in situations of motion and low-perfusion, and has been proven more accurate and reliable in the most challenging clinical settings by over 70 peer reviewed published clinical studies. Building on this technology platform, Masimo has recently introduced Masimo Rainbow SET, world's first device capable of noninvasively measuring carboxyhemoglobin, methemoglobin and oxyhemoglobin saturation levels in the blood

In clinical studies and in the field, Masimo Rainbow SET is already proving itself effective in detecting carbon monoxide poisoning in seconds, allowing accurate diagnosis and early treatment of a life-threatening problem that is frequently misdiagnosed as flu or migraine. In addition, a recent Johns Hopkins study found that methemoglobinemia, a potentially lethal condition that starves the tissues of oxygen, is much more common in hospitalized patients than previously realized.

About Amerinet
Amerinet is one of the most innovative and effective health care group purchasing organizations in the United States, partnering with members to improve their operating margins. More than 2,100 hospitals and 35,000 non-acute care facilities create new revenue and reduce expenses with Amerinet's tools for group purchasing, supply chain management, clinical consulting, revenue cycle management, and information and education.

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 100 clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact: Tom McCall
Vice President, Corporate Communications
949-790-7075
tmccall@masimo.com

New Study Concludes That Less Than Half of Hospitals Have Equipment On Site to Diagnose Carbon Monoxide Poisoning

Researchers suggest that a new, lower cost, noninvasive device that accurately measures carbon monoxide in the blood may be the solution

Irvine, California, July 11, 2006 - A recent study published in The Journal of Emergency Medicine titled "Carboxyhemoglobin Measurement by Hospitals: Implications for the Diagnosis of Carbon Monoxide Poisoning", examined the capability for diagnosing carbon monoxide poisoning at 204 acute care hospitals in the Pacific Northwest, concluding that only 44% of the hospitals had the necessary equipment on site to measure carbon monoxide levels in the blood. For the hospitals that did not have the testing equipment, the average time to receive results of a blood sample sent to another facility was over 15 hours.

The study states that carbon monoxide poisoning is common in the U.S. with over 40,000 emergency room visits annually for diagnosed cases. The authors also suggested that it is likely that there are many more undetected cases due to the fact that the symptoms for carbon monoxide poisoning are not obvious and often attributed to other causes. The authors stressed the importance of rapid diagnosis to speed treatment in order to prevent permanent brain injury.

Until recently, the only way to accurately measure the level of carbon monoxide in blood was through a test called CO-oximetry, which requires a blood sample to be taken and run through a laboratory CO-oximeter. The authors in this study found that, if the hospital had a CO-oximeter on site, it took, on average, 10 minutes to perform the test, but if the hospital had to send the sample offsite, it took over 15 hours, on average.

The lead researcher and author of the study, Neil B. Hampson, MD, stated, "There is a new noninvasive pulse CO-oximeter now available from Masimo Corporation that might help this situation. With the relatively high price of an invasive CO-oximeter, I would presume that the lack of availability is usually due to cost of the instrument. Given that the Masimo device is priced significantly lower, more hospitals should be able to afford them. In addition, if the test can be done in seconds, without taking a blood sample, I would expect many more cases of carbon monoxide poisoning to be detected. This could reduce morbidity due to carbon monoxide poisoning."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com

Masimo Recognized as Top 10 Innovator in Medical Device Industry

Masimo's patents are used as the basis for innovation 1,322% more than the industry average

Irvine, California June 28, 2006 - Masimo Corporation, the inventor of Pulse CO-Oximetry™ and Read-Through Motion and Low Perfusion pulse oximetry ranked 7^th overall in the Medical Device Industry in ipIQ's 2006 Patent Scorecard™. The Patent Scorecard is an industry-by-industry ranking of corporate innovation and combines a series of indicators to arrive at patent quality, technological strength and breadth of impact. It has historically been published in MIT's Technology Review and tracks the patent portfolios of more than 2,500 of the world's top technology firms.

ipIQ's Current-Impact Index™, or CII, showcases the broader significance of a company's patents by examining how impactful its patents are across the industry and in specific product categories in the most recent product cycles by measuring how frequently a company's patents are referenced as prior inventions by other patents. A CII of 100 represents average frequency. Masimo's CII was calculated to be 1,422, which means that Masimo's patents are referenced 1,322% more often than average. Masimo's CII score was more than 10 times the average for the medical device sector.

"Masimo's performance is stellar both within the medical device space and compared across every sector," stated Eric Gillespie, Executive Vice President and COO of ipIQ. "The Current-Impact Index is a quality measure designed to illustrate the strength of a company's technology portfolio. Masimo's Current-Impact Index was the highest score of the 2,500 plus companies included in the Patent Scorecard."

Joe E. Kiani, CEO and Chairman of Masimo stated, "Masimo was founded on the basis that to improve patient care and reduce cost of care, breakthroughs were necessary in the area of noninvasive vital signs monitoring. All of our peers were focusing on engineering longer battery life and smaller foot print conventional monitors, and while that is a worthy effort, we believed it should not be put in front of the real task of making accurate and reliable noninvasive vital signs monitors, which required inventions. We set out to solve a problem that the industry thought was unsolvable and our innovations have changed clinicians' expectations of noninvasive monitors and dramatically improved patient care and reduced cost of care."

Mike Petterson, Vice President of Clinical Research of Masimo stated, "Our first product line, Masimo Signal Extraction Technology (SET)® pulse oximetry was the first pulse oximetry FDA cleared for accuracy during patient motion and low perfusion and has ushered in a new performance standard for this critical vital sign. Last year, we introduced the second revolution in noninvasive vital signs monitoring, which we call Rainbow™. Like pulse oximetry, Rainbow is a spectroscopy based platform, but instead of using only two wavelengths of light, our Rainbow platform utilizes multiple wavelengths simultaneously. So far, we have two Rainbow measurements, the noninvasive and continuous measurements of carboxyhemoglobin and methemoglobin. We are working on additional noninvasive, continuous measurements and hope to announce others over the next few years."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

About ipIQ
ipIQ - Intellectual Property. Intelligence Quotient. - is the world's leading Intellectual Property advisor to investment banks, technology-driven companies, and governments. With over three decades of experience, ipIQ utilizes proprietary data, tools, analytics, and technology to leverage patent-based Intellectual Property as an asset class. The Patent Scorecard is published annually.

For additional information on the Patent Scorecared™ and ipIQ, go to www.ipIQ.com. ipIQ™, Science Linkage™, Current-Impact Index™, and Patent Scorecard™ are trademarks of ipIQ - Intellectual Property, Intelligence Quotient and are used with permission.

Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com

Contact:
Jude Reter
312-205-7037
jreter@ipIQ.com

AEA Honors Masimo with Innovative Medical Technology Award

Irvine, California May 23, 2006 - Masimo Corporation, the inventor of Pulse CO-Oximetry™ and Read-Through Motion and Low Perfusion Pulse Oximetry, was honored by the American Electronics Association's (AEA) Orange County Council at its Thirteenth Annual High Tech Awards ceremony. The AEA recognized the Masimo Rainbow SET Rad-57™ Pulse CO-Oximeter™, as the Innovative Product winner in the Medical Technology category.

Masimo is the inventor of read-through motion and low-perfusion pulse oximetry, a technology called Masimo SET®, which has been proven more accurate and reliable in the most challenging clinical settings by over 70 peer reviewed published clinical studies. Building on this technology platform, Masimo has recently introduced Masimo Rainbow SET™, a new technology that uses eight wavelengths of light to allow clinicians to capture and monitor an unprecedented array of patient physiological data, such as oxygen, carbon monoxide and methemoglobin, noninvasively. Masimo Rainbow SET capabilities will be available in Masimo monitors and in multi-parameter patient monitors produced by leading manufacturers.

The Rad-57 Pulse CO-Oximeter, the first FDA cleared Rainbow SET product from Masimo, is the first device that allows clinicians to detect and monitor carbon monoxide levels in the bloodstream non-invasively. In clinical studies and in the field, Masimo Rainbow SET is already proving itself effective in detecting carbon monoxide poisoning in seconds, allowing accurate diagnosis and early treatment of a life-threatening problem that is frequently misdiagnosed as flu or migraine. Masimo has also recently received FDA clearance for the noninvasive measurement of methemoglobin levels in the blood. A recent Johns Hopkins study found that methemoglobinemia, a potentially lethal condition that starves the tissues of oxygen, is much more common in hospitalized patients than previously realized.

Joe E. Kiani, Chief Executive Officer of Masimo stated "We are honored that the AEA has recognized Masimo with this award. From the very beginning, we always believed that our breakthrough signal extraction technologies would be widely applicable. Our first application, Masimo SET Signal Extraction Pulse Oximetry, has rapidly created a new performance standard for this critical vital sign. With our Masimo Rainbow SET platform, we are collecting a much more rich data stream separated from interference, enabling us to distinguish additional blood constituents. Our clinical and engineering teams are currently working to identify and qualify additional Rainbow parameters. We thank the AEA for this award and it's recognition of this innovative platform, and I thank my team for their brilliant efforts and tireless progress."

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

About AeA
AeA, founded in 1943, is a nationwide trade association that represents all segments of the technology industry and is dedicated solely to helping our members' top line and bottom line. We do this in partnership with our small, medium, and large member companies by lobbying governments at the state, federal, and international levels, providing access to capital and business opportunities, and offering select business services and networking programs. For more information, please visit www.aeanet.org.

Masimo and Dolphin Announce Settlement of Patent Dispute

Hawthorne, California - April 27, 2006, Dolphin Medical, Inc. today announced that it will discontinue its Dolphin ONE product line. The discontinuation is part of an agreement between Dolphin and Masimo Corporation, in which Masimo has agreed to release Dolphin and its affiliates from certain patent infringement claims.

About Dolphin Medical, Inc.

Dolphin Medical, Inc. is an OEM manufacturer and distributor of pulse oximetry sensors and digital pulse oximetry instruments. In addition to being an OEM provider the company in 2003 entered into a North American distribution agreement with ConMed Corporation to distribute a complete line of Nellcor compatible sensors. The company is headquartered in Hawthorne, CA and also has manufacturing facilities in Jahor Bahru, Malaysia and Hawthorne, CA. For further information on the company and its complete range of products, please visit, www.dolphinmedical.com.

About Masimo

Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact: Brad Langdale
949-297-7009
blangdale@masimo.com

Fukuda Denshi and Masimo Announce Pulse Oximetry Purchasing and Licensing Agreement

Fukuda Denshi's Dynascope DS-7300 Bedside Monitor is released with Masimo SET^®

April 18, 2006 -Fukuda Denshi Co. (Tokyo, Japan) and Masimo (Irvine, CA) today announced a purchasing and licensing agreement under which Fukuda Denshi will integrate Masimo Signal Extraction pulse oximetry technology (SET) into its future patient monitors. Fukuda Denshi is a leader in the research, development, manufacture and sale of patient monitors and medical devices. Masimo is the inventor of Pulse CO-Oximetry™ and Read-Through Motion and Low Perfusion Pulse Oximetry.

Fukuda Denshi and Masimo also announced the availability of the Masimo SET technology in Fukuda Denshi's Dynascope DS-7300 bedside monitor. The DS-7300 will incorporate all monitoring parameters contained in the Masimo SET Radical^® pulse oximeter, including Perfusion Index (PI) a relative assessment of blood flow at the monitoring site and Signal IQ™ (SIQ) technology, which allows clinicians to continuously monitor pulse identification and signal quality during low perfusion and patient motion conditions.

Masimo SET technology has been clinically proven in many independent studies to be accurate during patient motion and low perfusion. Studies show that Masimo SET has virtually eliminated false alarms while enhancing the ability to detect true alarms.

Kotaro Fukuda, President of Fukuda Denshi stated, "After a thorough review of all pulse oximetry technologies available in the marketplace, we concluded that Masimo SET is simply the best oximetry technology available for critical care. Masimo SET improves the performance and reliability of pulse oximetry measurement by substantially reducing the problems of motion artifact, low peripheral perfusion and most low signal-to-noise situations. We are proud to be able to offer this breakthrough technology to our customers."

"Fukuda Denshi is a leader in patient monitoring because they consistently seek to provide best-in-class technology in their monitoring solutions, "said Joe E. Kiani, CEO and Chairman of Masimo. "The Dynascope DS-7300 with Masimo SET is yet another example of Fukuda Denshi's commitment to improving patient outcomes by giving clinicians access to leading-edge technologies. Fukuda Denshi has a history of leadership in patient monitoring technologies that extends for over half a century. We are honored to have been selected as Fukuda Denshi's pulse oximetry platform, and to share in their tradition of excellence."

About Masimo

Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com

Masimo, SET, Signal Extraction Technology and Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.

Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com

About Fukuda Denshi

Fukuda Denshi Co., Ltd. was founded in 1939 as Fukuda Special Medical Electric Co. by the late Takashi Fukuda (former chairman of the board of directors) who took part in the development of Japan's first electrocardiograph in 1935. Now, the company has the sales points not only in each region of Japan but also throughout the world, and is well known as "Electrocardiograph's Fukuda" in the world. In addition, through technical and marketing tie-ups with domestic and foreign enterprises, the company is developing the business from the examination field to therapeutic equipment, home medicine and emergency lifesaving fields. Fukuda Denshi acquired the approval to the international standard ISO 9001 for quality system in 1995 and the approval to the international standard ISO 14001 for environment management system in 2003.

Federal District Court Upholds Antitrust Liability Verdict Against Tyco

Tyco found to unlawfully maintain monopoly power and to have utilized unlawful restraints of trade and exclusionary dealing arrangements in the pulse oximetry market

Irvine, California, March 29, 2006 - Masimo, the inventor of Pulse CO-Oximetry™ and read-through motion and low perfusion pulse oximetry, announced that a federal court in Los Angeles has upheld the jury liability verdict that Tyco Healthcare violated the antitrust laws through anticompetitive business practices specifically related to the sale of its Nellcor pulse oximetry products. On March 21, 2005, after a four-week trial, the jury found that Tyco had unlawfully maintained monopoly power, and that Tyco's sole-source agreements, bundling of unrelated products, market-share based compliance pricing contracts and co-marketing agreements with patient monitoring companies were unlawful restraints of trade and exclusionary dealing arrangements. The jury awarded Masimo $140 million in damages.

On March 22, 2006, the Court upheld the liability verdicts, but reversed the jury's findings based on 2 of the 4 specific practices, bundling and co-marketing agreements, and, as a result, set aside the jury's damages award and ordered a new trial on damages. The jury's original findings that Tyco violated Section 3 of the Clayton Act and Sections 1 and 2 of the Sherman Act were upheld by the Court.

Joe E. Kiani, Chairman and CEO of Masimo stated that, "We are happy that the court has upheld the jury's findings that Tyco's market share based pricing and single source contracts are illegal, which we hope will improve access to cost-effective innovative products that improve patient care. In hope of opening the markets even further to healthy competition, we will continue to press the courts on the practices of bundling of unrelated products. Medical products, from drugs, pacemakers to pulse oximeters, should be judged on their own merits and not based on artificial restraints on purchasing placed on the hospitals by large manufacturers. The American people should get the best care possible."

For many years, some large sellers of medical products have used bundling to exclude competition. Tyco, for example, reduces the discount on many other unrelated products if the hospital chooses to purchase just a small number of Masimo's pulse oximeters, even though the hospital continues to purchase just as much or even greater volume of the unrelated products. Thus, the discount on the whole bundle of products has the effect of being completely attributable to the pulse oximeters. The discount lost on the other unrelated products is sometimes large enough that it can even exceed the whole cost of the pulse oximeters. This makes the decision to purchase the product of clinical choice from Masimo very difficult for hospitals. These schemes can not only cause short term risk to certain patients and clinicians, because the particular hospital may have chosen the substandard product, but long term, such bundling practices will drive competition and innovation out of the healthcare space.

About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. Over 70 independent clinical studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. In 2005 Masimo introduced Rainbow SET and with it, Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, as well as oxygen saturation, pulse rate and perfusion index, allowing early detection and treatment of potentially life-threatening conditions.

Masimo, founded in 1989, has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.Masimo.com

Contact:
Brad Langdale
Masimo Corporation
blangdale@masimo.com
(949) 297-7009

Masimo Announces the FDA Clearance of Masimo Rainbow SET Rad-57cm

World's First Device Capable of Noninvasively Measuring